Resistant hypertension? Assessment of adherence by toxicological urine analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Chobanian, 2003, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure., Hypertension, 42, 1206, 10.1161/01.HYP.0000107251.49515.c2
Mancia, 2007, 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)., J Hypertens, 25, 1105, 10.1097/HJH.0b013e3281fc975a
Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research., Circulation, 117, e510, 10.1161/CIRCULATIONAHA.108.189141
Cuspidi, 2001, High prevalence of cardiac and extracardiac target organ damage in refractory hypertension., J Hypertens, 19, 2063, 10.1097/00004872-200111000-00018
Egan, 2011, Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008., Circulation, 124, 1046, 10.1161/CIRCULATIONAHA.111.030189
2011, A de, Segura J, Banegas JR, Gorostidi M, La Cruz JJ de, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring., Hypertension, 57, 898, 10.1161/HYPERTENSIONAHA.110.168948
Persell, 2011, Prevalence of resistant hypertension in the United States, 2003-2008., Hypertension, 57, 1076, 10.1161/HYPERTENSIONAHA.111.170308
Ahmed, 2011, Resistant hypertension: bad and getting worse., Hypertension, 57, 1045, 10.1161/HYPERTENSIONAHA.111.171520
Hill, 2011, Adherence and persistence with taking medication to control high blood pressure., J Am Soc Hypertens, 5, 56, 10.1016/j.jash.2011.01.001
van Wijk, 2005, Rate and determinants of 10-year persistence with antihypertensive drugs., J Hypertens, 23, 2101, 10.1097/01.hjh.0000187261.40190.2e
Vrijens, 2008, Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories., BMJ, 336, 1114, 10.1136/bmj.39553.670231.25
Burnier, 2003, Monitoring compliance in resistant hypertension: an important step in patient management., J Hypertens Suppl, 21, S37, 10.1097/00004872-200305002-00007
Gilbert, 1980, Predicting compliance with a regimen of dioxin therapy in family practice., CMAJ, 119-, 122
Dusing, 1998, Changes in antihypertensive therapy -- the role of adverse effects and compliance., Blood Press, 7, 313, 10.1080/080370598437187
Majumder, 2008, Criminal poisoning of commuters in Bangladesh: prospective and retrospective study., Forensic Sci Int, 180, 10, 10.1016/j.forsciint.2008.06.016
Bunker, 2011, How common is true resistant hypertension J Hum H, ypertens, 25, 137
Craig, 1985, Accuracy of indirect measures of medication compliance in hypertension., Res Nurs Health, 8, 61, 10.1002/nur.4770080112
Garg, 2005, Resistant hypertension revisited: a comparison of two university-based cohorts., Am J Hypertens, 18, 619, 10.1016/j.amjhyper.2004.11.021
Burnier, 2001, Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions., J Hypertens, 19, 335, 10.1097/00004872-200102000-00022
Okonofua, 2006, Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals., Hypertension, 47, 345, 10.1161/01.HYP.0000200702.76436.4b
Rose, 2009, Intensifying therapy for hypertension despite suboptimal adherence., Hypertension, 54, 524, 10.1161/HYPERTENSIONAHA.109.133389
Cushman, 2002, Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)., J Clin Hypertens (Greenwich), 4, 393, 10.1111/j.1524-6175.2002.02045.x
2012, A de, Banegas JR, Oliveras A, Gorostidi M, Segura J, La Cruz JJ de, et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs., J Hypertens, 30, 1211, 10.1097/HJH.0b013e328353634e
Maurer, 1986, Identification and differentiation of beta-blockers and their metabolites in urine by computerized gas chromatography-mass spectrometry., J Chromatogr, 382, 147, 10.1016/S0378-4347(00)83513-6
Maurer, 1999, Systematic toxicological analysis procedures for acidic drugs andor metabolites relevant to clinical and forensic toxicology andor doping control., J Chromatogr B Biomed Sci Appl, 733, 3, 10.1016/S0378-4347(99)00266-2
Maurer, 2010, Perspectives of liquid chromatography coupled to low- and high-resolution mass spectrometry for screening, identification, and quantification of drugs in clinical and forensic toxicology., Ther Drug Monit, 32, 324, 10.1097/FTD.0b013e3181dca295
Ojanpera, 2005, Application of accurate mass measurement to urine drug screening., J Anal Toxicol, 29, 34, 10.1093/jat/29.1.34
Maurer, 2004, Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization., J Chromatogr A, 1058, 169, 10.1016/S0021-9673(04)01308-1
Kristoffersen, 2007, Simultaneous determination of 6 beta-blockers, 3 calcium-channel antagonists, 4 angiotensin-II antagonists and 1 antiarrhythmic drug in postmortem whole blood by automated solid phase extraction and liquid chromatography mass spectrometry. Method development and robustness testing by experimental design., J Chromatogr B Analyt Technol Biomed Life Sci, 850, 147, 10.1016/j.jchromb.2006.11.030
Inui, 1981, Screening for noncompliance among patients with hypertension: is self-report the best available measure Med C, are, 19, 1061
Pladevall, 2010, La Figuera M de, et al. Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study)., Circulation, 122, 1183, 10.1161/CIRCULATIONAHA.109.892778
Hodge, 1979, Estimating compliance with diuretic therapy: urinary hydrochlorothiazide-creatinine ratios in normal subjects., Hypertension, 1, 537, 10.1161/01.HYP.1.5.537
Kronish, 2011, Meta-analysis: impact of drug class on adherence to antihypertensives., Circulation, 123, 1611, 10.1161/CIRCULATIONAHA.110.983874
Weinberger, 1988, Diuretics and their side effects. Dilemma in the treatment of hypertension., Hypertension, 11, II16, 10.1161/01.HYP.11.3_Pt_2.II16
Zhang, 2007, Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers., J Manag Care Pharm, 13, 664, 10.18553/jmcp.2007.13.8.664
Horne, 1999, Patients beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness., J Psychosom Res, 47, 555, 10.1016/S0022-3999(99)00057-4
Ubel, 2003, Misperceptions about beta-blockers and diuretics: a national survey of primary care physicians., J Gen Intern Med, 18, 977, 10.1111/j.1525-1497.2003.20414.x
Girvin, 2004, Comparison of the effects of a 7-day period of noncompliance on blood pressure control using three different antihypertensive agents., J Hypertens, 22, 1409, 10.1097/01.hjh.0000125440.28861.d6
Cramer, 1990, Compliance declines between clinic visits., Arch Intern Med, 150, 1509, 10.1001/archinte.1990.00390190143023
Jokisalo, 2003, Factors related to poor control of blood pressure with antihypertensive drug therapy., Blood Press, 12, 49
Choudhry, 2011, The implications of therapeutic complexity on adherence to cardiovascular medications., Arch Intern Med, 171, 814
2010, Beschluss des Gemeinsamen Bundesausschusses uber die Anderung der Arzneimittel-Richtlinie (AM-RL) in Anlage IV: Therapiehinweis zu Aliskiren vom 17. Dezember 2009 German National Association of Statutory Health Insurance Physicians. Decision of the Joint Federal Board (G-BA) on modifications to the pharmaceutical guidelines (AM-RL) in attachment IV: Therapy advice on Aliskiren, 17 December 2009., Dtsch Arztebl, 107, A1035
Geisler, 2012, Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension., J Am Coll Cardiol, 60, 1271, 10.1016/j.jacc.2012.07.029
Young, 2009, Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator., J Clin Hypertens (Greenwich), 11, 555, 10.1111/j.1751-7176.2009.00163.x
Schmieder, 2012, ESH position paper: renal denervation -- an interventional therapy of resistant hypertension., J Hypertens, 30, 837, 10.1097/HJH.0b013e328352ce78
Cherry, 2009, The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients., Value Health, 12, 489, 10.1111/j.1524-4733.2008.00447.x
Sokol, 2005, Impact of medication adherence on hospitalization risk and healthcare cost., Med Care, 43, 521, 10.1097/01.mlr.0000163641.86870.af